Form 4: KalVista Pharmaceuticals Acquired by Chiesi Farmaceutici

Director Nancy Stuart reports the disposal of stock options following the completion of KalVista Pharmaceuticals' acquisition by Chiesi Farmaceutici.

Summary

• KalVista Pharmaceuticals, Inc. (KALV) has been acquired by Chiesi Farmaceutici S.p.A. via a merger agreement.
• The acquisition was completed through a cash tender offer at a price of $27.00 per share.
• Director Nancy Stuart disposed of five tranches of stock options as part of the merger process.
• Options with exercise prices below the $27.00 merger consideration were converted into cash payments.
• Options with exercise prices equal to or greater than $27.00 were cancelled for no consideration.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing confirming the completion of a previously announced corporate acquisition.

Positives

• The merger provides liquidity to option holders whose exercise prices were below the $27.00 acquisition price.

Negatives

• Stock options with exercise prices of $34.27 were cancelled for no consideration as they were 'out-of-the-money' relative to the $27.00 merger price.

Risks

• The company is no longer a publicly traded entity following the merger completion.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Chiesi Farmaceutici S.p.A.; no further independent public guidance is provided.

Management Comments

• The securities were disposed of pursuant to the Agreement and Plan of Merger, dated as of April 29, 2026.

Industry Context

StockSavvy.ai notes that this acquisition reflects the ongoing trend of consolidation in the biopharmaceutical sector, where larger global players like Chiesi Farmaceutici are acquiring specialized firms to bolster their clinical pipelines.

Comparison to Industry Standards

• The $27.00 per share cash acquisition is a standard exit mechanism for shareholders in mid-cap biotech M&A transactions.
• The treatment of 'out-of-the-money' options is consistent with standard change-in-control provisions in executive compensation agreements.

Corporate Governance

Stakeholder Impact

• Shareholders receive $27.00 per share in cash.
• Option holders receive cash payouts for vested 'in-the-money' options.

Next Steps

• Delisting of KalVista Pharmaceuticals common stock from public exchanges.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Merger, Acquisition, Chiesi Farmaceutici, Form 4, Insider Transaction